Methimazole

Introduction Overview

Generic Name

methimazole

Brand Name

Tapazole, Northyx

Dosage Form

oral tablet (5 mg; 10 mg)

Drug Class

Antithyroid agents

Pharmacokinetics

Absorption: Methimazole is well absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations are typically reached within 1 to 2 hours after dosing. The absorption is rapid and virtually complete, which facilitates prompt onset of action in controlling hyperthyroid symptoms. Food intake does not significantly affect the bioavailability of methimazole, allowing it to be administered without regard to meals. There are no significant first-pass metabolism effects noted that reduce its efficacy.

Distribution: Once absorbed, methimazole is widely distributed throughout body tissues, with particular accumulation in the thyroid gland due to its therapeutic target. Plasma protein binding is relatively low, which contributes to its free active drug availability. The volume of distribution indicates moderate penetration into peripheral tissues, supporting its effectiveness in inhibiting thyroid hormone synthesis. Methimazole readily crosses the placental barrier and is detected in breast milk, necessitating caution in pregnancy and breastfeeding.

Metabolism: Methimazole undergoes minimal hepatic metabolism. It is primarily active in its administered form; however, some metabolism does occur via oxidation and conjugation pathways in the liver to produce inactive metabolites. The extent of metabolism is limited, reducing the burden on hepatic clearance mechanisms. Due to limited metabolism, methimazole exhibits less variability related to hepatic enzyme polymorphisms compared to other drugs.

Elimination: Excretion of methimazole and its metabolites occurs mainly through renal pathways. Approximately 50% or more of the administered dose is eliminated unchanged in the urine. The elimination half-life averages between 5 to 13 hours, supporting its dosing schedule of typically thrice daily administration to maintain steady therapeutic blood levels. The clearance rate may be altered in patients with renal impairment, requiring dosage adjustments. No significant biliary excretion is noted. The predictable elimination kinetics help maintain stable systemic exposure during long-term therapy.

Dosage Forms

Available Dosage Forms: Methimazole is commercially available as oral tablets in strengths of 5 mg and 10 mg. These tablets are formulated for oral use and are intended for systemic absorption in the management of hyperthyroidism.

Dosages for Adults and Adolescents: For adults, initial dosing depends on disease severity: mild hyperthyroidism typically begins with 15 mg orally per day; moderate severity requires 30 to 40 mg per day; severe cases may start at 60 mg per day. The maintenance dose is generally reduced to 5 to 15 mg daily. Doses are conventionally divided into three administrations approximately every 8 hours to maintain steady plasma concentrations.

Specific Patient Populations: Pediatric dosing is weight-based with an initial dose of approximately 0.4 mg/kg per day orally, divided into three doses. Maintenance therapy is about 0.2 mg/kg per day. In pregnancy and breastfeeding, methimazole is contraindicated due to potential fetal and neonatal adverse effects, including congenital anomalies and agranulocytosis risk; alternative treatments are preferred. Dose adjustments may be needed in patients with renal impairment. Elderly patients may require closer monitoring due to increased risk of adverse effects.

Mechanism Of Action

Methimazole acts primarily by inhibiting the synthesis of thyroid hormones through selective interference with thyroid peroxidase, an enzyme integral to the iodination of tyrosine residues in thyroglobulin and the coupling of iodotyrosines to form thyroxine (T4) and triiodothyronine (T3). By blocking thyroid peroxidase, methimazole prevents the organification of iodide and the coupling reactions, thereby reducing thyroid hormone production.

At the cellular level, this inhibition disrupts the hormone biosynthetic pathway within the thyroid follicular cells, lowering circulating levels of T3 and T4 and thereby attenuating the hypermetabolic state characteristic of hyperthyroidism. Methimazole does not inhibit the release of preformed thyroid hormones, so therapeutic effects may take several days to weeks to manifest clinically.

Methimazole’s biochemical interaction with thyroid peroxidase involves forming a complex that obstructs the enzyme’s active site, effectively halting iodide oxidation and hormone formation. This mechanism distinguishes it from iodine-based therapies, which inhibit hormone release but not synthesis. Compared to propylthiouracil, another antithyroid agent, methimazole is more potent with a longer half-life, allowing for less frequent dosing.

Clinical studies demonstrate that methimazole effectively ameliorates symptoms of Graves’ disease and toxic multinodular goiter, with improved thyroid hormone levels and reduced goiter size. Methimazole’s capacity to reduce thyroid hormone synthesis offers a valuable non-surgical and non-radioactive treatment option, especially in preparation for thyroidectomy or radioactive iodine therapy.

Pharmacological Actions

Inhibits thyroid peroxidase enzyme activity, reducing thyroid hormone synthesis.
Decreases production of thyroxine (T4) and triiodothyronine (T3), mitigating hyperthyroid symptoms.
Exerts antithyroid effects without affecting release of preformed hormone.
Reduces metabolic rate and associated systemic symptoms of hyperthyroidism.
Induces immunomodulatory effects that may decrease autoimmune activity in Graves' disease.
Supports preparation for definitive treatment such as thyroid surgery or radioactive iodine therapy.
Demonstrates a longer half-life compared to propylthiouracil, allowing convenient dosing schedules.
Does not exert direct cytotoxic effects on thyroid tissue.
Has low plasma protein binding enabling ready tissue distribution.
Minimal hepatic metabolism reduces risk of drug-drug metabolic interactions.

Therapeutic Or Clinical Uses

Management of hyperthyroidism including Graves’ disease and toxic multinodular goiter.
Preoperative preparation to normalize thyroid hormone levels before thyroidectomy.
Adjunctive treatment prior to radioactive iodine therapy to reduce thyroid hormone levels.
Treatment option when surgery or radioactive iodine therapy is contraindicated or declined.
Ameliorates systemic manifestations such as tachycardia, heat intolerance, and weight loss associated with hyperthyroidism.
Control of thyrotoxicosis to prevent thyroid storm in acute settings.
Used in pediatric hyperthyroidism cases with weight-based dosing regimens.
Alternative to propylthiouracil except during first trimester of pregnancy.
Integral in multimodal treatment strategies for autoimmune thyroid diseases.
Management of hyperthyroidism symptoms to improve patient quality of life.

Side Or Adverse Effects

Allergic reactions such as rash, hives, and pruritus.
Agranulocytosis leading to serious and sometimes fatal infections; characterized by fever, sore throat, and mouth ulcers.
Hepatotoxicity manifesting as nausea, upper abdominal pain, jaundice, and altered liver function tests.
Nausea, vomiting, and gastrointestinal discomfort.
Headache, dizziness, and somnolence.
Peripheral neuropathy including numbness and tingling sensations.
Arthralgia and myalgia (joint and muscle pain).
Hair loss (alopecia) and changes in hair texture.
Decreased or altered sense of taste.
Swollen lymph nodes in neck or jaw region.
Bleeding tendencies due to thrombocytopenia.
Rare cases of vasculitis and lupus-like syndrome.
Elevated liver enzymes without overt hepatitis in some patients.
Potential teratogenicity when used in pregnancy.
Hypothyroidism if overdosed or prolonged treatment without adjustment.

Precautions

Regular monitoring of complete blood counts to detect agranulocytosis early.
Frequent liver function tests due to risk of hepatotoxicity.
Caution in patients with pre-existing liver disease or blood dyscrasias.
Avoid use in pregnancy, especially during the first trimester due to teratogenic risk; use only if benefits outweigh risks.
Contraindicated during breastfeeding as drug passes into milk and may harm the infant.
Inform patients to report any signs of infection or unusual bleeding promptly.
Dose adjustment recommended in pediatric populations based on weight changes.
Careful use in elderly patients due to increased susceptibility to adverse effects.
Advise patients to avoid exposure to individuals with contagious infections due to immunosuppressive potential.
Proper patient education on adherence to dosing schedules to maintain steady drug levels.
Avoid abrupt discontinuation to prevent exacerbation of hyperthyroid symptoms.
Use caution when combined with other drugs affecting blood clotting.
Monitor thyroid function tests regularly to guide dose adjustments.
Patients should inform surgeons about methimazole use prior to any operative procedures.
Consider baseline renal function assessment, especially in long-term use.

Warnings

Methimazole is contraindicated in pregnancy and breastfeeding due to risk of fetal and neonatal harm.
Risk of severe and potentially fatal agranulocytosis requiring prompt medical attention upon symptom onset.
Potential for serious hepatotoxicity including cholestatic jaundice and hepatic necrosis.
Patients should be warned about symptoms of infection and advised to seek immediate care if these develop.
Close monitoring is essential to detect hypersensitivity reactions and severe skin reactions.
Not recommended for use in pediatric patients without appropriate medical supervision.
Avoid use in patients with known hypersensitivity to methimazole or related compounds.
Methimazole may cause hypothyroidism if dosing is excessive or not properly managed.
Risk of bleeding and bruising necessitates caution in patients on anticoagulants.
Potential for interaction with beta blockers and other cardiovascular drugs requires monitoring.
Do not breast-feed during methimazole treatment to prevent neonatal exposure.
Patients undergoing surgery should inform healthcare providers of methimazole use to manage perioperative thyroid risks.
Withdrawal should be gradual to avoid rebound hyperthyroidism.
Use with caution in patients with immunodeficiency or hematological disorders.

Contraindication

Known hypersensitivity or allergy to methimazole or any component of the formulation.
Pregnancy, especially during the first trimester, due to teratogenicity risk.
Breastfeeding mothers due to drug transfer into breast milk and potential neonatal adverse effects.
Patients with a history of agranulocytosis induced by methimazole or similar antithyroid drugs.
Severe liver failure or active hepatic disease.
Patients with preexisting blood cell disorders without close monitoring.
Use in pediatric patients without medical guidance is contraindicated.
Concomitant use with drugs that can cause bone marrow suppression without medical supervision.
Hypersensitivity to other thioamide drugs such as propylthiouracil.
Patients unable to comply with required clinical and laboratory monitoring.
Known coagulation disorders without specialist management.
Uncontrolled infections or immunocompromised status.
Severe renal impairment until further safety data available.
Prophylactic use without confirmed diagnosis of hyperthyroidism.
Use in patients with untreated thyroid cancer without multidisciplinary management.

Drug Interactions

Warfarin and other oral anticoagulants can have enhanced anticoagulant effects when combined with methimazole, necessitating frequent INR monitoring.
Beta blockers such as atenolol, propranolol, and carvedilol may be co-administered to control hyperthyroid symptoms; care required to monitor cardiovascular status.
Digoxin levels may be altered due to changes in thyroid hormone levels secondary to methimazole therapy.
Theophylline clearance may be affected, requiring dosage adjustments.
Concomitant use with other bone marrow suppressants increases risk of leukopenia and agranulocytosis.
Drugs that impact hepatic metabolism may alter methimazole levels although methimazole undergoes minimal metabolism.
Iodine-containing agents can interfere with methimazole's efficacy by competing or affecting thyroid hormone synthesis.
Potential additive immunosuppressive effects with other immunomodulatory drugs.
Antidiabetic agents may require adjustment due to metabolic changes as thyroid status normalizes.
Concurrent use with lithium can affect thyroid function and necessitates careful monitoring.
Interactions with corticosteroids may impact immune-related effects and adrenal function.
Herbal supplements affecting blood clotting (e.g., ginkgo biloba) need careful consideration when combined.
Concomitant use with beta-adrenergic agonists may necessitate cardiovascular monitoring.
Antacids and cholestyramine may reduce methimazole absorption if taken simultaneously.
Drugs that cause neutropenia increase the risk of methimazole-related agranulocytosis.

Preparations Of The Drug

Oral tablets: 5 mg, 10 mg strengths suitable for precise dosing and titration.
Available as branded products Tapazole and Northyx.
Manufactured for oral administration with standard excipients ensuring stability and bioavailability.
Packaged in blister packs or bottles to maintain drug integrity under room temperature storage conditions.
Formulated for use in adults and pediatric patients with dosing individualized per body weight.
Supplied with clear labeling for dosage instructions emphasizing thrice daily administration.
Not available in injectable or liquid preparations; oral tablet remains the standard delivery form.
Manufacturing complies with regulatory standards to ensure purity and consistent potency.
Storage recommendations specify room temperature away from moisture and heat to preserve efficacy.
Accompanied by patient information leaflets detailing side effect recognition and necessary precautions.
Can be compounded into adjusted doses by pharmacists for pediatric or special needs cases upon physician request.
Produced with consideration to minimize allergic excipients in formulation.
Packaging includes warning labels regarding pregnancy and breastfeeding contraindications.
Available in various international markets with regulatory approvals for hyperthyroidism treatment.
Generic formulations provide cost-effective alternatives with bioequivalence to branded versions.